Anti-Microbial Savior BioteQ Co., Ltd.
Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. It develops technology patenting of medical fungi. The company also provides MEDIACE, an antibacterial Ingredient containing skin-friendly materials and medicinal fungal extracts. In addition, it provides customized functional face masks. The company was founded in 2018 and is… Read more
Anti-Microbial Savior BioteQ Co., Ltd. (6864) - Net Assets
Latest net assets as of June 2025: NT$192.78 Million TWD
Based on the latest financial reports, Anti-Microbial Savior BioteQ Co., Ltd. (6864) has net assets worth NT$192.78 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$201.09 Million) and total liabilities (NT$8.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$192.78 Million |
| % of Total Assets | 95.87% |
| Annual Growth Rate | 5.18% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 56.24 |
Anti-Microbial Savior BioteQ Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Anti-Microbial Savior BioteQ Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Anti-Microbial Savior BioteQ Co., Ltd. (2021–2024)
The table below shows the annual net assets of Anti-Microbial Savior BioteQ Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$237.31 Million | +96.04% |
| 2023-12-31 | NT$121.05 Million | -29.70% |
| 2022-12-31 | NT$172.19 Million | -15.56% |
| 2021-12-31 | NT$203.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Anti-Microbial Savior BioteQ Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15803600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$441.41 Million | 186.01% |
| Total Equity | NT$237.31 Million | 100.00% |
Anti-Microbial Savior BioteQ Co., Ltd. Competitors by Market Cap
The table below lists competitors of Anti-Microbial Savior BioteQ Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
489480
KQ:489480
|
$13.62K |
|
Annabidiol Corp
PINK:ACBD
|
$13.62K |
|
Yuanta SPAC 9
KQ:430700
|
$13.62K |
|
BTYU11
SA:BTYU11
|
$13.64K |
|
Reliance Cotton Spinning Mills Ltd
KAR:RCML
|
$13.58K |
|
CHINA STATE CONSTRU
MU:C4S1
|
$13.57K |
|
Universal New Energy Holding Group, Inc.
PINK:UNEH
|
$13.57K |
|
67B
STU:67B
|
$13.57K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anti-Microbial Savior BioteQ Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 121,053,000 to 237,310,000, a change of 116,257,000 (96.0%).
- Net loss of 74,517,000 reduced equity.
- New share issuances of 190,448,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-74.52 Million | -31.4% |
| Share Issuances | NT$190.45 Million | +80.25% |
| Other Changes | NT$326.00K | +0.14% |
| Total Change | NT$- | 96.04% |
Book Value vs Market Value Analysis
This analysis compares Anti-Microbial Savior BioteQ Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 6.16x to 6.79x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$7.97 | NT$49.10 | x |
| 2022-12-31 | NT$6.73 | NT$49.10 | x |
| 2023-12-31 | NT$4.73 | NT$49.10 | x |
| 2024-12-31 | NT$7.23 | NT$49.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anti-Microbial Savior BioteQ Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12175.98%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-31.40%) is below the historical average (-25.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -10.96% | -25398.86% | 0.00x | 1.08x | NT$-42.74 Million |
| 2022 | -18.43% | -1176.75% | 0.01x | 1.06x | NT$-48.96 Million |
| 2023 | -42.78% | -7112.91% | 0.01x | 1.06x | NT$-63.89 Million |
| 2024 | -31.40% | -12175.98% | 0.00x | 1.05x | NT$-98.25 Million |
Industry Comparison
This section compares Anti-Microbial Savior BioteQ Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anti-Microbial Savior BioteQ Co., Ltd. (6864) | NT$192.78 Million | -10.96% | 0.04x | $13.58K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |